Shares in Mylan (NSDQ:MYL) rose slightly this morning after the pharmaceutical company reported its first-quarter financial results, missing analysts’ sales and earnings estimates.
The company posted profits of $87.1 million, or 17¢ per share, on sales of $2.68 billion for the 3 months ended March 31, for bottom-line growth of 31% on sales loss of -1% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan misses estimates on The Street with Q1 results appeared first on MassDevice.
from MassDevice https://ift.tt/2wqPJGD
Cap comentari:
Publica un comentari a l'entrada